You are here

By: Cheryl Proval

Welcome to the 7th annual Radiology 100 group survey results. Hopefully the survey will cause some of the radiology groups to pause and ask what has changed in the marketplace this year, and what could/will happen in the next year? As you review the survey and compare this year’s results with last year’s, you will notice that many of the radiology groups are not growing in terms of the number of radiologists. Both productivity increases and decreased utilization have had obvious impacts on the industry. 

Download the Results

Growing a business in a mature industry is difficult, and radiology is now a mature industry. Growth can come through two main areas: organic growth and mergers/acquisitions. The survey highlights some of mergers that we have seen in...

Editorial
By: Cheryl Proval
Get ready to rollout LDCT lung cancer screening
Departments
By: Cheryl Proval
Get ready for a revolution in radiological communications was the message of a panel of presenters on “Web Technologies: The New Healthcare IT Standard.”
Departments
By: Gregory N. Nicola, MD
The ability to use the ACR registries to satisfy  PQRS requirements transforms a perfunctory bureaucratic exercise into an authentic QI activity.
Features
By: Cynthia Keen
The radiology department of the future already is under construction in departments throughout the country
Departments
By: Cheryl Proval
To meet demands to cut costs in healthcare, administrators are reaching for the obvious—line item expenses on the profit-and-loss statement—with counterproductive results. 
Features
By: Dave Pearson
Representatives of five practice models—academic, private practice, multispecialty, employed and teleradiology—share thoughts on their relative strengths and weaknesses
Departments
By: Eric B. LoMonaco
The Affordable Care Act of 2010 mandates that CMS implement the Hospital Value–Based Purchasing (VBP) Program, which incorporates several quality domains.
Features
By: Richard Conroy, PhD
A NIBIB director describes three areas of research with big-impact potential and poised to go from bench to bedside.